Journal of Oncology
Volume 2009 (2009), Article ID 458528, 5 pages
doi:10.1155/2009/458528
Research Article

A Population-Based Clinical Trial of Irinotecan and Carboplatin

Derick Lau,1,2 Minh Huynh,1,2 and Jewel Johl1,2

1Davis Cancer Center, University of California, Sacramento, CA 95817, USA
2Department of Veterans Affairs Northern California Health Care System (VANCHCS), University of California, Sacramento, CA 95817, USA

Received 30 September 2008; Revised 20 December 2008; Accepted 8 January 2009

Academic Editor: Michael A. Carducci

Copyright © 2009 Derick Lau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. A. Eisenhauer, P. J. O'Dwyer, M. Christian, and J. S. Humphrey, “Phase I clinical trial design in cancer drug development,” Journal of Clinical Oncology, vol. 18, no. 3, pp. 684–692, 2000.
  2. E. L. Korn, D. Midthune, T. T. Chen, L. V. Rubinstein, M. C. Christian, and R. M. Simon, “A comparison of two phase I trial designs,” Statistics in Medicine, vol. 13, no. 18, pp. 1799–1806, 1994. View at Publisher · View at Google Scholar
  3. M. J. Ratain, R. Mick, R. L. Schilsky, and M. Siegler, “Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents,” Journal of the National Cancer Institute, vol. 85, no. 20, pp. 1637–1643, 1993. View at Publisher · View at Google Scholar
  4. R. H. J. Mathijssen, R. J. van Alphen, J. Verweij, et al., “Clinical pharmacokinetics and metabolism of irinotecan (CPT-11),” Clinical Cancer Research, vol. 7, no. 8, pp. 2182–2194, 2001.
  5. M. J. Ratain, “Irinotecan dosing: does the CPT in CPT-11 stand for “can't predict toxicity”?,” Journal of Clinical Oncology, vol. 20, no. 1, pp. 7–8, 2002.
  6. R. Simon, B. Freidlin, L. Rubinstein, S. G. Arbuck, J. Collins, and M. C. Christian, “Accelerated titration designs for phase I clinical trials in oncology,” Journal of the National Cancer Institute, vol. 89, no. 15, pp. 1138–1147, 1997. View at Publisher · View at Google Scholar
  7. C. Louvet, T. André, E. Gamelin, et al., “A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients,” Bulletin du Cancer, vol. 91, no. 12, pp. 279–284, 2004.
  8. P.-L. Kellokumpu-Lehtinen, K. Sunela, I. Lehtinen, H. Joensuu, and J. Sjöström-Mattson, “A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes,” Clinical Breast Cancer, vol. 7, no. 5, pp. 401–405, 2006. View at Publisher · View at Google Scholar
  9. H. J. Ross, L. L. Hart, P. M. Swanson, et al., “A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma,” Lung Cancer, vol. 54, no. 1, pp. 69–77, 2006. View at Publisher · View at Google Scholar · View at PubMed
  10. K. Noda, Y. Nishiwaki, M. Kawahara, et al., “Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer,” The New England Journal of Medicine, vol. 346, no. 2, pp. 85–91, 2002. View at Publisher · View at Google Scholar · View at PubMed
  11. D. Lau, J. Johl, M. Huynh, et al., “Population-based phase I trial of irinotecan and epirubicin,” American Journal of Clinical Oncology, vol. 31, no. 3, pp. 226–230, 2008.
  12. A. H. Calvert, D. R. Newell, L. A. Gumbrell, et al., “Carboplatin dosage: prospective evaluation of a simple formula based on renal function,” Journal of Clinical Oncology, vol. 7, no. 11, pp. 1748–1756, 1989.
  13. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Publisher · View at Google Scholar
  14. K. James, E. Eisenhauer, M. Christian, et al., “Measuring response in solid tumors: unidimensional versus bidimensional measurement,” Journal of the National Cancer Institute, vol. 91, no. 6, pp. 523–528, 1999. View at Publisher · View at Google Scholar
  15. T. A. Ryan and B. L. Joiner, “Minitab: a statistical computing system for student and researchers,” The American Statistician, vol. 27, pp. 222–225, 1974.
  16. H. L. Alder and E. B. Roessler, Probability and Statistics, W. H. Freeman, New York, NY, USA, 4th edition, 1968.
  17. L. Iyer, S. Das, L. Janisch, et al., “UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity,” Pharmacogenomics Journal, vol. 2, no. 1, pp. 43–47, 2002. View at Publisher · View at Google Scholar
  18. K. Araki, K.-I. Fujita, Y. Ando, et al., “Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer,” Cancer Science, vol. 97, no. 11, pp. 1255–1259, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. S. F. Jones, H. A. Burris, III, J. D. Hainsworth, et al., “Phase I. Trial of irinotecan plus carboplatin in two dose schedules,” Oncology, vol. 17, no. 5, supplement 5, pp. 36–40, 2003.
  20. K. Yonemori, N. Katsumata, N. Yamamoto, et al., “A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy,” Cancer, vol. 104, no. 6, pp. 1204–1212, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. G. Chen, M. Huynh, L. Fehrenbacher, et al., “Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1401–1404, 2009.